Cite
APA Citation
Conaghan, P. G., Nowak, M., Du, S., Luo, Y., Landis, J., Pachai, C., Fura, A., Catlett, I. M., Grasela, D. M., & Østergaard, M. (2023). evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. Lancet, 5, e263–e273. http://access.bl.uk/ark:/81055/vdc_100184745900.0x000001